The Humanized CD40 Antibody SGN-40 Demonstrates Pre-clinical Activity That is Enhanced By Lenalidomide in Chronic Lymphocytic Leukemia

Antibody-based therapies, such as rituximab and alemtuzumab, have contributed significantly to the treatment of Chronic Lymphocytic leukemia (CLL). The CD40 antigen is expressed predominantly on B-cells and represents a potential target for immune-based therapies. SGN-40 is a humanized IgG1 monoclon...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Lapalombella, Rosa, Gowda, Aruna, Joshi, Trupti, Mehter, Najma, Cheney, Carolyn, Lehman, Amy, Chen, Ching-Shih, Johnson, Amy J., Caligiuri, Michael A., Tridandapani, Susheela, Muthusamy, Natarajan, Byrd, John C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2009
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2776067/
https://ncbi.nlm.nih.gov/pubmed/19183192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2008.07548.x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk